ORAL-LYO-FMT: Microbiome Restoration Therapy

Indication: Recurrent Clostridioides difficile Infection (rCDI) and Irritable Bowel Syndrome with Diarrhea (IBS-D)

Status: Clinical Phase II

Platform Overview: This program utilizes a standardized, lyophilized Oral Fecal Microbiota Transplantation (FMT) formulation. By preserving the full spectrum of microbial diversity in a stable, encapsulated format, we aim to restore intestinal homeostasis without the risks associated with invasive delivery.

Scientific Leadership: The project is led by Dr. Christine Lee, a globally recognized pioneer in FMT research. Her previous landmark studies established the efficacy of non-invasive microbiota transfer, providing the clinical foundation for this next-generation oral therapy.

Clinical Enrollment: We are currently enrolling patients in multicenter Phase II trials to evaluate the long-term safety, microbial engraftment efficiency, and clinical resolution of dysbiosis-related disorders.

NASAL-PPGV-FLU: Pan-Respiratory Mucosal Vaccine

Indication: COVID-19, Influenza A, and Influenza B

Status: Preclinical

The GVNP Vaccine Platform: Our proprietary Gas Vesicle Nanoparticle (GVNP) platform serves as a highly immunogenic scaffold. By genetically anchoring multi-valent viral antigens onto the GV surface, we achieve high-density epitope display that mimics native viral structures.

Mucosal Immunity Advantage: Unlike traditional intramuscular injections, nasal administration directly stimulates Mucosa-Associated Lymphoid Tissue (MALT). This induces potent secretory IgA responses at the respiratory epithelium—the primary site of viral entry—effectively neutralizing pathogens before systemic infection occurs and significantly reducing viral shedding.

DERMAL-PPGV-CAN: Personalized Cancer Immunotherapy

Indication: Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Preclinical

Precision Neoantigen Targeting: This personalized vaccine leverages our Neoantigen AI to identify patient-specific tumor mutations. These high-confidence neoantigens are then integrated into the GVNP carrier, creating a bespoke therapeutic designed to overcome tumor immune evasion.

Intradermal Delivery Kinetics: We utilize the intradermal route to exploit the high concentration of professional Antigen-Presenting Cells (APCs), such as Langerhans cells, in the dermis. This delivery strategy optimizes antigen trafficking to draining lymph nodes, fostering a robust and sustained CD8+ T-cell mediated anti-tumor response specifically against malignant B-cell clones.